Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51

Journal of the American College of Cardiology

Volumn 62, Issue 4, 2013, Pages 286-290

  Gibson, C Michael ^a,b   Chakrabarti, Anjan K ^a   Mega, Jessica ^b   Bode, Christophe ^c   Bassand, Jean Pierre ^d   Verheugt, Freek W A ^e   Bhatt, Deepak L ^b,f   Goto, Shinya ^g   Cohen, Marc ^h   Mohanavelu, Satishkumar ^b   Burton, Paul ⁱ   Stone, Gregg ^j   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^e Onze Lieve Vrouwe Gasthuts   (Netherlands)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j Howard Hughes Medical Institute   (United States)

more..

Author keywords

acute coronary syndrome(s); factor Xa inhibitor; rivaroxaban; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STENT THROMBOSIS; TREATMENT DURATION;

ACS; ACUTE CORONARY SYNDROME(S); DAPT; DUAL ANTIPLATELET THERAPY; FACTOR XA INHIBITOR; PCI; PERCUTANEOUS CORONARY INTERVENTION; RIVAROXABAN; STENT THROMBOSIS;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PLATELET AGGREGATION INHIBITORS; PYRIDINES; STENTS; THIOPHENES; THROMBOSIS; TREATMENT OUTCOME;

EID: 84880276837     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.03.041     Document Type: Article

References (11)

1. D.L. Fischman, M.B. Leon, D.S. Baim Stent Restenosis Study Investigators A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease N Engl J Med 331 1994 496 501
2. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K. Ho, R. D'Agostino, and D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
3. M.B. Leon, D.S. Baim, and J.J. Popma A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting N Engl J Med 339 1998 1665 1671
4. C.L. Grines, R.O. Bonow, and D.E. Casey Jr. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J Am Coll Cardiol 49 2007 734 739
5. M.E. Bertrand, V. Legrand, and J. Boland Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study Circulation 98 1998 1597 1603
6. E.M. Becker, E. Perzborn, and A. Klipp Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis J Thromb Haemost 10 2012 2470 2480
7. N. Tamura, I. Kitajima, and Y. Kawamura Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions Circ J 73 2009 540 548
8. J.L. Mega, E. Braunwald, and S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
9. C.M. Gibson, J.L. Mega, and P. Burton Rationale and design of the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome - Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome Am Heart J 161 2011 815 821 e816
10. J.H. Alexander, R.D. Lopes, and S. James Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
11. P. Tricoci, Z. Huang, and C. Held Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33